Single high-dose buprenorphine for opioid craving during withdrawal. by Ahmadi, Jamshid et al.
UCLA
UCLA Previously Published Works
Title
Single high-dose buprenorphine for opioid craving during withdrawal.
Permalink
https://escholarship.org/uc/item/5j70n9p6
Journal
Trials, 19(1)
ISSN
1745-6215
Authors
Ahmadi, Jamshid
Jahromi, Mina Sefidfard
Ghahremani, Dara
et al.
Publication Date
2018-12-10
DOI
10.1186/s13063-018-3055-z
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Ahmadi et al. Trials          (2018) 19:675 
https://doi.org/10.1186/s13063-018-3055-zRESEARCH Open AccessSingle high-dose buprenorphine for opioid
craving during withdrawal
Jamshid Ahmadi1*, Mina Sefidfard Jahromi1, Dara Ghahremani2 and Edythe D. London2,3,4Abstract
Background: Opioid use disorder is one of the most prevalent addiction problems worldwide. Buprenorphine is
used as a medication to treat this disorder, but in countries where buprenorphine is unavailable in combination
with naloxone, diversion can be a problem if the medication is given outside a hospital setting.
Objective: The objective of this research is to evaluate the effect of a single, high dose of buprenorphine on
craving in opioid-dependent patients over 5 days of abstinence from use of other opioids. The primary goal was to
determine the safety and efficacy of buprenorphine during withdrawal in a hospital setting.
Methods: Ninety men who used opium, heroin, or prescribed opioids and met DSM-5 criteria for opioid use
disorder (severe form) were randomized to three groups (n = 30 per group) to receive a single, sublingual dose of
buprenorphine (32, 64, or 96 mg). The study was conducted in an inpatient psychiatric ward, with appropriate
precautions and monitoring of respiratory and cardiovascular measures. Buprenorphine was administered when the
patients were in moderate opiate withdrawal, as indicated by the presence of four to five symptoms. A structured
clinical interview was conducted, and urine toxicology testing was performed at baseline. Self-reports of craving
were obtained at baseline and on each of the 5 days after buprenorphine administration.
Findings: Craving decreased from baseline in each of the three groups (p < 0.0001), with a significant interaction
between group and time (p < 0.038), indicating that groups with higher doses of buprenorphine had greater reduction.
Conclusions: A single, high dose of buprenorphine can reduce craving during opioid withdrawal; additional studies
with follow-up are warranted to evaluate safety.
Keywords: Buprenorphine, Craving, Opioid dependence, Opioid withdrawalBackground
Buprenorphine, a partial agonist at mu-opioid receptors
and an antagonist at delta- and kappa-opioid receptors,
has been evaluated for the management of opioid use
disorder [1–13]. Regarded as safer than methadone [5–
7], buprenorphine at a dose of 8 mg is as effective as 60
mg of methadone [8]. Buprenorphine is well absorbed
after sublingual administration [4, 9, 10], and its partial
agonist action at mu-opioid receptors contributes to a
safer profile of buprenorphine over methadone, with
minimal respiratory depressant effects [14–26].
The purpose of this study was to assess the effects
of single, high-dose buprenorphine administration (32,* Correspondence: Jamshid_Ahmadi@yahoo.com
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(http://creativecommons.org/publicdomain/ze64, or 96 mg) on opiate craving during initial abstin-
ence. Craving is an essential feature of substance use
disorders, as evidenced by its recent addition to the
diagnostic criteria for these disorders in the Diagnos-
tic and Statistical Manual of Mental Disorders, Fifth
Edition (DSM-5; American Psychiatric Association) [3,
17, 20, 21], and it persists after detoxification to
promote relapse [3, 17, 21, 22]. Buprenorphine was
administered in a hospital setting to reduce the possi-
bility of diversion of the medication, which is much
more likely if the formulation does not include nalox-
one, which is included in some formulations for this
purpose (e.g., Suboxone®). Such combined formula-
tions are not available in Iran.
Doses of buprenorphine higher than those that are
commonly administered clinically (i.e., 16–24mg) were
used to increase the effective half-life of the medicationle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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36–72 h after sublingual use) and to enhance mu-opioid
receptor occupancy. A single high dose was examined
because repeated buprenorphine administration in out-
patients increases the possibility of dependence, diver-
sion, and abuse (this is also based on our clinical
experiences in Iran) [3, 18, 21, 22, 27, 28]. Buprenor-
phine was administered rather than methadone due to
the risk of overdose with a single, high dose of metha-
done [22–24]. Common practice in our center is for
opioid-dependent patients to undergo withdrawal as
inpatients under supervision, to leave the hospital after
detoxification without medication-assisted treatment,
and then to return for psychosocial follow-up. If a
patient requires medication when evaluated at follow-up,
appropriate management, such as buprenorphine main-
tenance treatment, is initiated.
Methods and materials
Participants and procedures
This study was approved and monitored by the Commit-
tee of Ethics of Shiraz University of Medical Sciences; it
adhered to the Declaration of Helsinki Ethical Principles
for Medical Research Involving Human Subjects. At
screening, participants were interviewed and examined for
eligibility by a board certified psychiatrist. We explained
the goals of the study, and guaranteed confidentiality. All
the patients gave written informed consent prior to enter-
ing the study. The participants were male inpatients at the
main psychiatric ward, where only men were hospitalized.
Prior to admission, they had been abusing opium, heroin,
and illicit or prescribed opioids for at least 1 year. Patients
who met initial eligibility requirements on screening were
administered the Structured Clinical Interview for DSM-5,
Clinical Version (SCID-I), by a board certified psychiatrist
to determine if they met the criteria for opioid use dis-
order (listed in DSM-5). Daily opioid abuse for at least 1
year was a requirement. Patients were excluded if they
had substance use disorders involving drugs other than
opioids (excluding tobacco), organic mental disorders,
major medical diseases (hepatic, renal, cardiovascular, pul-
monary, gastrointestinal, or malignant diseases), or any
type of psychosis. The study was a double-blind random-
ized trial. The first 90 eligible treatment-seeking patients
who referred to our ward were randomly assigned to the
three buprenorphine arms (n = 30 per group).
Buprenorphine tablets (a single dose) were adminis-
tered sublingually, while the patient was in moderate
opioid withdrawal from opioids, as indicated by the
presence of four or five symptoms of opioid withdrawal
[3]. The buprenorphine doses tested were 32 mg, which
is the maximum dosage currently used clinically, and
two other doses that were twice and three times as
much, respectively. The interview, examination, andquestioning were performed at the treatment hospital.
To enhance confidentiality and validity of the informa-
tion, data were obtained from the patient in the absence
of accompanying family or acquaintances.
A visual analog scale (VAS) that has been used previ-
ously [16–19] was used to measure the opioid craving,
with a range of 0–10 (0 = no craving and 10 = severe de-
sire, craving, or temptation all the time). Patients
responded to the statement: Rate your craving over the
past day. Measurements of craving were taken each morn-
ing. The hospital system covered sublingual tablets.
Patients did not receive any form of compensation. During
the hospitalization course, they did not receive any other
methods of coping with craving (e.g., group sessions
focused on relaxation/mindfulness/distraction, etc.).
A placebo group was not included because of the high
possibility of severe withdrawal without active pharma-
cological treatment. The pills had the same shape and
color. They were given in 8-mg increments. Everyone
received the same number of pills. Placebo pills were
used so that the patients did not know what dose they
were receiving. Tablets were administered based on the
tolerance of the patient.
Out of 90 patients, each group (30 patients) received
32mg, 64 mg, or 96 mg of buprenorphine. Over the next
5 days, craving and adverse effects were evaluated. The
degree of opioid craving was calculated and assessed
through patients’ reports. Urine drug toxicology was car-
ried out using thin-layer chromatography (TLC) before
administration of the single dose, twice a week and at
the end of the 5-day trial. To ensure safety, adverse
effects, vital signs, respiration, and gastrointestinal ef-
fects were monitored every hour for the first day, and
then every 6 h. For the current study, withdrawal was
done in the hospital because we administered “high
doses” instead of standard doses. We advocate using a
single dose on an inpatient basis and then discharging
the patients drug-free (without medication assistance
treatment) and with an appointment for close psycho-
social follow-up [2, 18, 20]. In any follow-up, if a patient
needs medication, we start appropriate treatment such
as buprenorphine maintenance treatment.
Data analysis
Statistical analyses included both inferential and descrip-
tive statistical methods. Data analysis was conducted
using SPSS version 21. A repeated-measures two-way
analysis of variance (ANOVA) was used, with day and
group as the two factors and Greenhouse-Geisser cor-
rection for violation of sphericity. Post hoc t tests of dif-
ferences in means were performed, and chi-square
testing was used to test for differences in frequencies
among the groups. The threshold for statistical signifi-
cance was p < 0.05, both tails.
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Data were collected from 90 men whose mean age
was 32.85 ± 6.97 years. All the patients whom were
screened entered the research study, and all of those
who entered completed the trial (Fig. 1and Table 1).
During the course of the study, no illicit opioid use
was detected (based on daily interview and urine toxi-
cology). All the patients had normal liver and kidney
function before enrollment.
The Consolidated Standards of Reporting Trials
(CONSORT) flow and the checklist for the study are
shown in Fig. 1 and Table 1.
The three groups did not differ on demographic charac-
teristics (Table 2). Table 3 presents craving scores of the
three groups during the 5-day interval of treatment. A
significant main effect of day (F (2, 2.16) = 199.96, p <
0.0001) but not group (F (2, 87) = 1.67, p = 0.194) and a
significant group-by-day interaction (F (2, 4.32) = 2.52, p <
0.05) were found.
Post hoc t tests revealed that the 32-mg group differed
significantly from both the 64-mg and 96-mg groups, with
lower craving observed for the higher dose groups. No sig-
nificant differences were observed between the 64-mg and
96-mg groups, suggesting that the maximal effect on crav-
ing reduction was achieved with the 64-mg dose (Table 4).Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flowchart ofAdverse effects
To ensure safety, side effects, vital signs, respiration, and
gastrointestinal effects were measured and monitored
every hour for the first day, and then every 6 h. Nine pa-
tients developed notable side effects. Two (both in the
96-mg group) developed significant hypotension (blood
pressure of 75/50 and 80/45, respectively) and were
treated with hydration. Two (both in the 32-mg group)
developed nausea. Five (two in the 64-mg group and
three in the 96-mg group) developed both nausea and
vomiting. Patients who had nausea or vomiting were
treated with antiemetic medications. No severe respira-
tory, cardiovascular, or gastrointestinal adverse effects
were observed.
Discussion
Buprenorphine has been evaluated extensively for the
treatment of opioid use disorder [2–4]. In chronic use, it
is considered for reducing craving and increasing
long-term abstinence from illicit opioids [8].
Here we show that a single dose of buprenorphine (32
mg, 64 mg, and 96mg) can provide a rapid, effective,
and safe means of reducing opioid craving at 5 days
post-treatment, 64 mg more so than 32mg, with no
greater effect at 96 mg. The comparable efficacy of thethe patients in this trial
Table 1 CONSORT 2010 checklist of information to include when reporting a randomized trial
Section/topic Item no. Checklist item Reported on
page no.
Title and abstract
1a Identification as a randomized trial in the title 1
1b Structured summary of trial design, methods,
results, and conclusions (for specific guidance
see CONSORT for abstracts)
1
Introduction
Background and objectives 1a Scientific background and explanation of rationale 2
2b Specific objectives or hypotheses 2
Methods
Trial design 2a Description of trial design (such as parallel, factorial)
including allocation ratio
2
2b Important changes to methods after trial
commencement (such as eligibility criteria),
with reasons
2
Participants 2a Eligibility criteria for participants 2
2b Settings and locations where the data were
collected
2
Interventions 2 The interventions for each group with sufficient
details to allow replication, including how and
when they were actually administered
2
Outcomes 2a Completely defined pre-specified primary and
secondary outcome measures, including how
and when they were assessed
2
2b Any changes to trial outcomes after the trial
commenced, with reasons
2
Sample size 2a How sample size was determined 2
2b When applicable, explanation of any interim
analyses and stopping guidelines
NA
Randomization:
Sequence generation 2a Method used to generate the random allocation
sequence
2
2b Type of randomization; details of any restriction
(such as blocking and block size)
2
Allocation concealment mechanism 2 Mechanism used to implement the random
allocation sequence (such as sequentially
numbered containers), describing any steps
taken to conceal the sequence until interventions
were assigned
2
Implementation 2 Who generated the random allocation sequence,
who enrolled participants, and who assigned
participants to interventions
2
Blinding 2a If done, who was blinded after assignment to
interventions (for example, participants, care
providers, those assessing outcomes) and how
2
2b If relevant, description of the similarity of interventions NA
Statistical methods 2a Statistical methods used to compare groups for
primary and secondary outcomes
2
2b Methods for additional analyses, such as subgroup
analyses and adjusted analyses
2
Results
Participant flow (a diagram is
strongly recommended)
3a For each group, the numbers of participants who
were randomly assigned, received intended treatment,
and were analyzed for the primary outcome
2
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Table 1 CONSORT 2010 checklist of information to include when reporting a randomized trial (Continued)
Section/topic Item no. Checklist item Reported on
page no.
3b For each group, losses and exclusions after
randomization, together with reasons
3
Recruitment 3a Dates defining the periods of recruitment
and follow-up
3
3b Why the trial ended or was stopped 3
Baseline data 3 A table showing baseline demographic and
clinical characteristics for each group
3
Numbers analyzed 3 For each group, number of participants
(denominator) included in each analysis and
whether the analysis was by original assigned
groups
3
Outcomes and estimation 3a For each primary and secondary outcome, results
for each group, and the estimated effect size and
its precision (such as 95% confidence interval)
3
3b For binary outcomes, presentation of both absolute
and relative effect sizes is recommended
3
Ancillary analyses 3 Results of any other analyses performed, including
subgroup analyses and adjusted analyses,
distinguishing pre-specified from exploratory
3
Harms 3 All important harms or unintended effects in each
group (for specific guidance see CONSORT for harms)
3
Discussion
Limitations 6 Trial limitations, addressing sources of potential bias,
imprecision, and, if relevant, multiplicity of analyses
3
Generalizability 6 Generalizability (external validity, applicability) of
the trial findings
6
Interpretation 6 Interpretation consistent with results, balancing benefits
and harms, and considering other relevant evidence
6
Other information
Registration 6 Registration number and name of trial registry 6
Protocol 6 Where the full trial protocol can be accessed, if available 6
Funding 6 Sources of funding and other support (such as supply of
drugs), role of funders
6
Table 2 Demographic characteristics of the patients
Group 32 mg
n = 30 (33.33%)
64 mg
n = 30 (33.33%)
96 mg
n = 30 (33.33%)
Total
n = 90 (100%)
Chi-square F df p valuea
Age (years)b “M (SD).” 34.20 ± 7.30 32.83 ± 8.16 31.53 ± 5.035 32.85 ± 6.97 1.10 2 0.337
Drug abuse (years)b “M (SD).” 9.75 ± 5.86 9.43 ± 6.52 10.50 ± 6.29 9.89 ± 6.17 0.232 2 0.794
Jobc
“n (%)”
Unemployed 12 (40) 19 (63.3) 14 (40) 43 (47.8) 8.719 6 0.190
Employed 2 (6.7) 3 (10.0) 2 (6.7) 7 (7.8)
Self-employed 16 (53.3) 7 (23.3) 16 (53.3) 39 (43.3)
Educationc
“n (%)”
Unable to read/write 1 (3.3) 1 (3.3) 0 (0) 2 (2.2) 4.918 8 0.766
Primary school 11 (36.7) 8 (26.7) 10 (33.3) 29 (32.2)
High school 12 (40) 17 (56.7) 15 (50) 44 (48.9)
University education 6 (20) 4 (13.3) 4 (13.3) 14 (15.6)
Marital statusc
“n (%)”
Married 15 (50) 21 (70) 14 (46.7) 50 (55.6) 3.870 2 0.144
Single 15 (50) 9 (30) 16 (53.3) 40 (44.4)
aThe three groups were compared by ANOVA (continuous measurement variables) and chi-square analysis (categorical data)
bNumbers tabulated indicate means ± standard deviation (SD)
cNumbers tabulated indicate how many participants were in each category
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Table 3 Craving scores (means and standard deviations) of the
three groups
Group (Buprenorphine, mg)
Day
32
n = 30
64
n = 30
96
n = 30
Baseline 7.23 ± 3.51 6.93 ± 3.54 7.56 ± 3.53
Day 1 4.46 ± 3.95 4.96 ± 2.90 4.00 ± 2.75
Day 2 2.56 ± 3.23 3.03 ± 2.23 1.00 ± 1.74
Day 3 1.70 ± 2.39 0.900 ± 1.37 0.366 ± 0.927
Day 4 1.23 ± 1.86 0.300 ± 0.749 0.233 ± 0.727
Day 5 0.700 ± 1.14 0.100 ± 0.402 0.00 ± 0.00
Ahmadi et al. Trials          (2018) 19:675 Page 6 of 764- and 96-mg dosages may reflect occupancy of
mu-opioid receptors to the same degree over the short
(5 days) post-treatment evaluation time. Doses higher
than 16–24mg are thought to increase the effective
half-life of buprenorphine; therefore, high doses (64 mg
and 96 mg) would be expected to be more effective than
32mg, as observed here.
Administration of buprenorphine as a single large
dose decreases concerns about compliance as well as
the probability of dependence, diversion, and abuse.
Moreover, cost considerations are favorable, especially
when considering administration to outpatients with-
out hospitalization. A single-dose treatment also is
suited to transition to antagonist treatment, which
could probably be started at an earlier time than with
a traditional detoxification schedule lasting many days
or even weeks. Moreover, it could also provide a
more suitable titration of agonist treatment, poten-
tially with lower maintenance doses being required. In
patients who are unsuitable for or decline medication
-assisted treatment, it would allow more rapid referral
to either an intensive outpatient or residential treat-
ment program.
Strengths of this study included the randomized clinical
trial design and a reasonable number of patients, carefully
diagnosed using DSM-5 criteria and urine drug screening
tests. However, the study had some limitations, including
its recruitment of men only. It would be important to
know if the results are generalizable to both sexes and to
determine the duration of the effect of single-dose bupre-
norphine on opioid craving. Administration of a high dose
of buprenorphine may be far more likely to result in re-
spiratory or cardiovascular complications in older patientsTable 4 Post hoc t test p values of the three groups
Group Baseline
p value
Day 1
p value
Day 2
p value
Day 3
p value
Day 4
p value
Day 5
p value
32 vs 64 0.743 0.553 0.469 0.069 0.004 0.001
32 vs 96 0.716 0.579 0.017 0.003 0.002 0.000
64 vs 96 0.489 0.252 0.002 0.223 0.835 0.583with underlying occult disorders, especially sleep apnea,
than in younger patients.
Conclusions
The single-dose buprenorphine treatment provided safe
and rapid treatment of opioid craving. The outcomes sup-
port further investigations of the use of a single high dose
of buprenorphine as a safe and effective protocol to early
treatment of these patients. Moreover, the findings support
further investigations of a single dose to decrease opioid
craving over more extended time frames.
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